你知道吗？在基因编辑领域，新的突破常常能引发轩然大波。最近，广州市宝创生物技术有限公司成功取得了一项关于CRISPR-Cas13a系统的非连续靶标激活模式及应用的专利，这一消息无疑让无数生物科技爱好者与研究人员感到振奋。然而，这项新专利到底意味着什么？它将如何改变未来的基因治疗与生物技术发展？

CRISPR gene editing and next-generation sequencing (NGS) have transformed clinical and life sciences research. CRISPR permits the selective targeting and editing of specific nucleotide sequences ...

CRISPR-Cascade, including sample preparation, requires about half an hour, making it the fastest available bloodstream infection diagnostic. There is also the potential to improve sample prep ...